Study title:
Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 µg, 2 inhal. b.i.d.) compared to Pulmicort® (budesonide 100 µg, 2 inhal. b.i.d.) and Pulmicort (budesonide 100 µg, 2 inhal. b.i.d.) plus Oxis® (formoterol 4.5 µg, 2 inhal. b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children. A double-blind, double-dummy, randomised, parallel-group, phase III, multicentre 12-week study.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases [C08]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: BUDESONIDE |
ATC code: |
Document link:
|
Document date:
|
Study number: SD-039-0688 |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|